Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 4/20 | 0.49 |
| ▸ | DRD3 | P35462 | 4/20 | 0.49 |
| ▸ | HTR1A | P08908 | 3/20 | 0.49 |
| ▸ | HTR2A | P28223 | 3/20 | 0.49 |
| ▸ | DRD1 | P21728 | 2/20 | 0.49 |
| ▸ | DRD5 | P21918 | 2/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6839410 | 0.86 | RAB9A (0.73) | MAPTPOLBPKMRAB9ALMNA | |
| SCHEMBL11711465 | 0.84 | MAPT (0.59) | MAPTPOLBPKMRAB9ALMNA | |
| SCHEMBL28954641 | 0.83 | MAPT (0.77) | MAPTPOLBPKMRAB9ALMNA | |
| SCHEMBL6843584 | 0.82 | DRD2 (0.54) | MAPTTP53LMNASMN1; SMN2DRD2 | |
| SCHEMBL2489051 | 0.75 | HRH3 (0.70) | MEN1KMT2A | |
| SCHEMBL4747687 | 0.74 | HRH3 (0.55) | MAPTPOLBPKMRAB9ALMNA | |
| SCHEMBL28689384 | 0.74 | MAPT (0.67) | MAPTPOLBPKMRAB9ALMNA | |
| SCHEMBL2487709 | 0.73 | HRH3 (0.64) | MEN1KMT2A | |
| SCHEMBL7131184 | 0.73 | MAPK1 (0.64) | MAPTLMNAMAPK1SMN1; SMN2MEN1 | |
| SCHEMBL23092834 | 0.72 | MAPT (0.64) | MAPTPOLBPKMLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040116443-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC | 2004-06-17 | — | — | US | disclosed |
| US-20030158208-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2003-08-21 | — | — | US | disclosed |
| US-6548502-B2 | Preventing disorder selected from pathological gambling, attention deficit disorder with hyperactivity disorder, substance addiction such as drug and alcohol and sex in a mammals by administering pyrido(1,2-a) pyrazine derivatives | PFIZER INC | 2003-04-15 | — | — | US | disclosed |
| US-20020049209-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2002-04-25 | — | — | US | disclosed |
| EP-1177792-A2 | Dopamine D4 Ligands for the treatment of novelty-seeking disorders | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | disclosed |
| EP-0775118-A1 | BENZIMIDAZOLE DERIVATIVES HAVING DOPAMINERGIC ACTIVITY | PFIZER INC. (US) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996004250-A1 | BENZIMIDAZOLE DERIVATIVES HAVING DOPAMINERGIC ACTIVITY | PFIZER INC. (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049209-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | SLC6A3, DRD4, DRD2 | MAPT 1380/4885POLB 4125/4885PKM 4105/4885 |
| US-20030158208-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | SLC6A3, DRD4, DRD2 | MAPT 1380/4885POLB 4125/4885PKM 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.